Thymulin: Zinc-Bound Thymic Nonapeptide

📄 7 PubMed citations

A nine-amino-acid peptide hormone secreted by thymic epithelial cells. Biologically active only when bound to zinc — without Zn²⁺ it is the inactive precursor FTS.

🔬 Often confused with Thymalin (a multi-peptide thymus extract) and Thymosin Alpha-1 (a 28-aa peptide) — Thymulin is a single, defined 9-amino-acid zinc complex.

Amino acid residues (nonapeptide)

Zn²⁺ ion required for activity

Year FTS first characterized (Bach)

Mechanism of Action

How It Works

🧲

Zinc Binding (Obligatory)

Thymulin is a peptide-zinc complex. The 9-residue chain (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) is biologically inactive without Zn²⁺; the zinc-free form is termed FTS. This is why thymulin activity falls in zinc deficiency — there is no functional thymulin without the cofactor. (PMID 2657247, 15003367)

🧬

T-Cell Differentiation

Originally isolated as a thymic factor that induces T-cell differentiation markers on pre-T precursors. Thymulin shaped the early understanding of how thymic epithelial cells direct intra- and extra-thymic T-cell maturation. (PMID 15003367, 2657247)

🧠

Neuroendocrine Crosstalk

Thymulin secretion is regulated by pituitary hormones and, reciprocally, thymulin stimulates pituitary prolactin (PRL) and thyrotropin (TSH) release — bidirectional hypophyso-thymic axis. Neonatal thymulin gene therapy alters corticotrope morphology in nude mice. (PMID 9818729, 21360440)

🛡️

Anti-Inflammatory Signaling

In rodent models, thymulin reduces NF-κB and p38 MAPK activation, lowers TNF-α / IL-6 / IL-17, and dampens microglial activity in CFA-induced inflammatory pain. Inhaled thymulin gene therapy reversed asthma pathology in mice. (PMID 30851702, 32577505, 33779346, 29795607)

Data

What the Data Shows

CFA inflammatory pain — p38 MAPK phosphorylation

PMID 30851702 — Int Immunopharmacol 2019 (rat, spinal)

↓ significant

Asthma — chronic airway inflammation + fibrosis

PMID 32577505 — Sci Adv 2020 (mouse, inhaled gene therapy)

Near-complete reversal

Type 1 diabetes — pro-inflammatory cytokines

PMID 33779346 — Int J Immunopathol Pharmacol 2021 (mouse, STZ model)

TNF-α / IL-17 ↓

Chronic septic inflammation — fever + apoptosis

PMID 29795607 — PLoS One 2018 (mouse, LPS)

Reduced; nanoparticle form more potent

Pituitary axis — PRL / TSH release

PMID 9818729 — Mech Ageing Dev 1998 (age-dependent)

Stimulated (young > old)

Bottom Line

Key Takeaways

✅ What We Know

Thymulin is a single defined 9-amino-acid peptide hormone secreted by thymic epithelial cells; activity requires bound Zn²⁺.
Plasma thymulin titers decline progressively with age, paralleling thymic involution.
Verified in vivo: inhaled thymulin gene therapy reversed key asthma pathology in mice (PMID 32577505, Sci Adv 2020).
Anti-inflammatory and anti-hyperalgesic in CFA pain, sepsis, and STZ-diabetes rodent models — mechanism converges on NF-κB / p38 MAPK / TNF-α suppression.
Bidirectional hypophyso-thymic axis: pituitary hormones regulate thymulin; thymulin stimulates PRL and TSH release in young animals.

⚠️ What We Don't Know

Thymulin is NOT FDA-approved and is not a recognized medicine in the US, EU, or UK.
Human clinical trial data is sparse — most modern evidence is rodent or in vitro.
Reported dosing protocols come from limited Russian/post-Soviet clinical reports — there is no established human dose-response curve for non-clinical use.
Most translational work in the last decade uses gene therapy or nanoparticle delivery — bare synthetic thymulin pharmacokinetics in humans are poorly characterized.
Often confused with Thymalin (a multi-peptide extract) and Thymosin Alpha-1 (a 28-aa peptide); the three are NOT interchangeable.

FAQ

Frequently Asked Questions

What is Thymulin?

Thymulin is a nine-amino-acid peptide hormone (pGlu-Ala-Lys-Ser-Gln-Gly-Gly-Ser-Asn) produced exclusively by thymic epithelial cells. It is biologically active only when bound to zinc — the zinc-free form is the inactive precursor FTS (Facteur Thymique Sérique). It was first characterized by Bach and colleagues in the early 1970s. (PMID 15003367)

How is Thymulin different from Thymalin and Thymosin Alpha-1?

Three commonly confused thymic compounds: Thymulin is a single 9-amino-acid zinc-binding peptide; Thymosin Alpha-1 is a single 28-amino-acid peptide; Thymalin is a multi-peptide thymus extract (its activity is attributed mainly to the dipeptides KE and EW). All three originate from the thymus and act on immunity, but they differ in structure, mechanism, and regulatory status.

Why does Thymulin require zinc?

The nonapeptide backbone alone is the inactive precursor FTS. Stoichiometric binding of a single Zn²⁺ ion induces the conformation responsible for thymulin's biological effects on T-cell precursors and the pituitary. This is why zinc deficiency depresses functional thymulin activity even when peptide is present. (PMID 2657247, 15003367)

What evidence supports anti-inflammatory effects?

In a 2020 Science Advances study, a single inhaled dose of nanoparticle-delivered thymulin gene therapy near-completely reversed chronic asthma pathology in mice (PMID 32577505). In CFA-induced inflammatory pain, thymulin suppressed spinal microglia, p38 MAPK phosphorylation, and TNF-α / IL-6 (PMID 30851702). Similar reductions in NF-κB / TNF-α / IL-17 were reported in STZ-diabetes (PMID 33779346) and chronic LPS sepsis (PMID 29795607).

Is Thymulin FDA-approved or safe to use?

No. Thymulin is not FDA-approved and is classified as a research compound. There is no established human dose-response curve, no peer-reviewed safety database for chronic use, and most modern translational evidence uses gene therapy or nanoparticle delivery — not subcutaneous synthetic peptide. Treat it strictly as a research molecule.